Escalated Application of Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis Patients

Motor Neuron Disease Clinical Trial

Official title:

Safety and Efficacy of Mesenchymal Stem Cells Escalated Application in Amyotrophic Lateral Sclerosis Patients: Study Design of a Phase I Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02987413
• Other study ID #: HospitalMCG
• Secondary ID: IEPSaoLucas
• Status: Completed
• Phase: Phase 1
• First received: July 1, 2016
• Last updated: August 4, 2017
• Start date: April 28, 2015
• Est. completion date: April 5, 2017

Study information

• Verified date: August 2017
• Source: Hospital e Maternidade Dr. Christóvão da Gama
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that selectively affects motor neurons in the brain and spinal cord, leading to bulbar, respiratory, and limb weakness. There is no effective treatment, and the disease usually progresses to death within 2 to 4 years. The therapeutic plasticity of mesenchymal stem cells (MSCs) may be an attractive therapy to this complex disease, turning MSCs strong candidates for cellular therapy in ALS.

Design—A phase 1 open-safety clinical trial. 4 patients will be selected according to a restricted inclusion and exclusion criteria and after 2 escalated infusions of MSCs, there will be a follow up period of one year Methods - Primary endpoint: safety of mesenchymal autologous stem cells infusions escalated in two intrathecal administrations in patients with ALS defined as severe adverse events (SAe). Secondary endpoints: clinical response, laboratorial and magnetic resonance imaging of patients submitted to cellular escalating doses applied in the study. Quality of life, according to El Escorial criteria, ALSFR scale and functional scales.

Conclusion: This study is a primary step before a large randomized double-blind clinical trial for ALS. It is expected to confirm the safety of escalated MSCs therapy in ALS patients, initial data of efficacy in addition to improved quality of life.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3
• Est. completion date: April 5, 2017
• Est. primary completion date: March 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Women and males over 18-year-old.

• Diagnosis of ALS in agreement with the criteria of "EL SCORE"

• Less than 24 months of evolution of the disease (from the beginning of the symptoms).

• Good understanding of the protocol and aptitude to grant the informed consent

• Infertile women (post-menopause or hysterectomized)

• Brazilian citizen and permanent resident.

Exclusion Criteria:

• Any significant medical condition (congestive heart failure, angina, respiratory failure, and others)

• Any auto-immune disease

• Any malignant diseases

• Systemic infection

• Mental illness

• Depressive state

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Sclerosis

Intervention

Biological:
• Autologous Mesenchymal stem cells (MSCs)
2 intrathecal autologous MSCs infusions (1x10^8 cells) will be performed, escalated from 30 days apart

Locations

Country	Name	City	State
Brazil	Hospital e Maternidade Dr Christovao da Gama	Santo Andre	Sao Paulo
Brazil	Instituto de Ensino e Pesquisas - IEP-São Lucas	Sao Paulo	SP

Sponsors (4)

Lead Sponsor	Collaborator
Hospital e Maternidade Dr. Christóvão da Gama	Clinica Jordy Sinapse, IEP São Lucas - Instituto de Ensino e Pesquisa, TECHLIFE - Centro de Tecnologia Celular

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serious Adverse Events related to the treatment	Serious Adverse Events (Death, Life-threatening, Disability or Permanent Damage) will be monitored and documented during follow up	12 months
Secondary	Revised ALS Functional Rating Scale (ALSFRS-R)	Quality of life from patients according to functional scales will be evaluated before and after interventions with 1, 3, 6 and 12 months.	12 months

External Links

•   Institutional website